ABLYNX FILES REGISTRATION STATEMENT FOR A PROPOSED GLOBAL OFFERING
(Thomson Reuters ONE) -
REGULATED INFORMATION - INSIDE INFORMATION
GHENT, Belgium, 2 October 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY], a
late-stage clinical biopharmaceutical company utilising its proprietary
Nanobody® platform to develop treatments for a broad range of therapeutic
indications with an unmet medical need, announced today that it has filed a
Registration Statement on Form F-1 with the U.S. Securities and Exchange
Commission for a proposed global offering of its ordinary shares, including
ordinary shares in the form of American Depositary Shares ("ADSs"). Ablynx
expects to offer its ADSs to investors in the United States and its ordinary
shares to qualified investors in a concurrent private placement in Europe and
countries outside of the United States and Canada in the global offering.
Investors other than qualified investors under applicable law will not be
eligible to participate in this potential private placement. All ordinary shares
and ADSs to be sold in the global offering will be offered by Ablynx. The global
offering is subject to market and other conditions, including the effectiveness
of the above-referenced registration statement. Ablynx's ordinary shares are
currently listed on Euronext Brussels and Ablynx has made an application to have
its ADSs listed on the NASDAQ Global Select Market under the symbol "ABLX."
BofA Merrill Lynch, J.P. Morgan and Jefferies are acting as joint book-running
managers for the offering. Baird, Bryan, Garnier & Co. and Ladenburg Thalmann
are acting as co-managers for the offering.
The securities referred to in this release are to be offered only by means of a
prospectus. When available, copies of the preliminary prospectus can be obtained
from BofA Merrill Lynch at NC1-004-03-43, 200 North College Street, 3rd floor,
Charlotte North Carolina 28255-0001, Attn: Prospectus Department, or by email at
dg.prospectus_requests(at)baml.com; from J.P. Morgan at Attn: Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at
(866) 803-9204; or from Jefferies at 520 Madison Avenue, 2nd Floor, New York,
New York 10022, Attn: Equity Syndicate Prospectus Department, or by email at
Prospectus_Department(at)Jefferies.com.
A registration statement relating to and describing the terms of the offering
has been filed with the U.S. Securities and Exchange Commission but has not yet
become effective. The securities may not be sold, nor may offers to buy be
accepted, prior to the time the registration statement becomes effective.
This press release does not constitute an offer to sell or the solicitation of
an offer to buy securities, and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
that jurisdiction.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
45 proprietary and partnered programmes in development in various therapeutic
areas including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. Ablynx has collaborations with multiple pharmaceutical
companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co.,
Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi
and Taisho Pharmaceuticals.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste(at)ablynx.com
Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx(at)consilium-comms.com
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed
to be, "forward-looking statements". These forward-looking statements can be
identified by the use of forward-looking terminology, including the terms
"believes", "estimates", "anticipates", "expects", "intends", "seeks", "may",
"will", "could", "should" or similar expressions, and include statements Ablynx
makes concerning the intended results of its strategy. By their nature, forward-
looking statements involve risks and uncertainties and readers are cautioned
that any such forward-looking statements do not constitute any guarantee of
future performance. Ablynx's actual results may differ materially from those
predicted by the forward-looking statements. Ablynx undertakes no obligation to
publicly update or revise forward-looking statements, except as may be required
by law.
Important Information
In this announcement, certain information is disclosed that constituted inside
information prior to this announcement.
No public offering will be made and no one has taken any action that would, or
is intended to, permit a public offering in any country or jurisdiction, other
than the United States, where any such action is required, including in the
European Economic Area. In the European Economic Area, with respect to any
Member State that has implemented Directive 2003/71/EC, as amended (together
with any applicable implementing measures in any Member State, the "Prospectus
Directive"), the transaction to which this press release relates will only be
available to, and will be engaged in only with, qualified investors in that
Member State within the meaning of the Prospectus Directive.
In addition, in the United Kingdom, the transaction to which this press release
relates will only be available to, and will be engaged in only with, investment
professionals falling within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), qualified
investors falling within Article 49(2)(a) to (d) of the Order, and other persons
to whom this announcement may lawfully be communicated (all such persons
together being referred to as "relevant persons"). The securities referred to
herein are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with relevant persons. Any person who is not a relevant person should not act or
rely on this communication or any of its contents.
pdf version of the press release:
http://hugin.info/137912/R/2138900/818778.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="European Metals Holdings Limited: Memorandum of Understanding Signed with Czech Government
Datum: 02.10.2017 - 23:06 Uhr
Sprache: Deutsch
News-ID 562138
Anzahl Zeichen: 8168
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX FILES REGISTRATION STATEMENT FOR A PROPOSED GLOBAL OFFERING"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
